|
|
Blood, 15 July 2004, Vol. 104, No. 2, pp. 340-349.
Prepublished online as a Blood First Edition Paper on March 30, 2004; DOI 10.1182/blood-2004-02-0518.
Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation
Thorsten Kaiser,
Haytham Kamal,
Andreas Rank,
Hans-Jochem Kolb,
Ernst Holler,
Arnold Ganser,
Bernd Hertenstein,
Harald Mischak, and
Eva Maria Weissinger
From Mosaiques Diagnostics & Therapeutics and Hannover Medical School, Departments of Hematology/Oncology and Nephrology, Hannover, Germany; Jose-Carreras-Unit, Klinikum Großhadern, München, Germany; and the Department of Hematology, University of Regensburg, Regensburg, Germany.
A phase 1 diagnostic study was performed to evaluate a novel technology for clinical proteom research based on capillary electrophoresis and mass spectrometry. Urine from 40 patients after hematopoietic stem cell transplantation (HSCT; 35 allogeneic, 5 autologous) and 5 patients with sepsis was collected for a period of 100 days and analyzed. More than 1000 different polypeptides could be detected in individual samples. Polypeptide patterns excreted in the urine of patients were significantly different from those of healthy volunteers. No significant differences were detected comparing different conditioning regimens. The aim of this study was to identify polypeptide patterns functioning as early indicators of graft-versus-host disease (GVHD). Eighteen patients developed GVHD after allogeneic HSCT. Sixteen differentially excreted polypeptides formed a pattern of early GVHD markers, allowing discrimination of GVHD from patients without complications with 82% specificity and 100% sensitivity, cross-validated. Inclusion of 13 sepsis-specific polypeptides allowed us to distinguish sepsis from GVHD with a specificity of 97% and a sensitivity of 100%. Sequencing 2 prominent GVHD-indicative polypeptides led to the identification of a peptide from leukotriene A4 hydrolase and a peptide from serum albumin. The data reveal that capillary electrophoresis and mass spectrometry allow identification of biomarkers for a variety of diseases or related complications. (Blood. 2004;104:340-349)

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
F. Ravandi, A. Aribi, S. O'Brien, S. Faderl, D. Jones, A. Ferrajoli, X. Huang, S. York, S. Pierce, W. Wierda, et al.
Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms
J. Clin. Oncol.,
November 10, 2009;
27(32):
5425 - 5430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Socie
Graft-versus-host disease: proteomics comes of age
Blood,
January 8, 2009;
113(2):
271 - 272.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Paczesny, O. I. Krijanovski, T. M. Braun, S. W. Choi, S. G. Clouthier, R. Kuick, D. E. Misek, K. R. Cooke, C. L. Kitko, A. Weyand, et al.
A biomarker panel for acute graft-versus-host disease
Blood,
January 8, 2009;
113(2):
273 - 278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Decramer, A. G. de Peredo, B. Breuil, H. Mischak, B. Monsarrat, J.-L. Bascands, and J. P. Schanstra
Urine in Clinical Proteomics
Mol. Cell. Proteomics,
October 1, 2008;
7(10):
1850 - 1862.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hori, Y. Naishiro, H. Sohma, N. Suzuki, N. Hatakeyama, M. Yamamoto, T. Sonoda, Y. Mizue, K. Imai, H. Tsutsumi, et al.
CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease
Blood,
April 15, 2008;
111(8):
4403 - 4412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Weissinger, E. Schiffer, B. Hertenstein, J. L. Ferrara, E. Holler, M. Stadler, H.-J. Kolb, A. Zander, P. Zurbig, M. Kellmann, et al.
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Blood,
June 15, 2007;
109(12):
5511 - 5519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Fliser, J. Novak, V. Thongboonkerd, A. Argiles, V. Jankowski, M. A. Girolami, J. Jankowski, and H. Mischak
Advances in Urinary Proteome Analysis and Biomarker Discovery
J. Am. Soc. Nephrol.,
April 1, 2007;
18(4):
1057 - 1071.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ganser, M. A. Morgan, and E. M. Weissinger
Going from genes to proteins in myelodysplastic syndromes
PNAS,
January 23, 2007;
104(4):
1109 - 1110.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Pisitkun, R. Johnstone, and M. A. Knepper
Discovery of Urinary Biomarkers
Mol. Cell. Proteomics,
October 1, 2006;
5(10):
1760 - 1771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Mohty, D. Blaise, C. Faucher, N. Vey, R. Bouabdallah, A.-M. Stoppa, F. Viret, G. Gravis, D. Olive, and B. Gaugler
Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation
Blood,
December 15, 2005;
106(13):
4407 - 4411.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Z. Haeggstrom
Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis
J. Biol. Chem.,
December 3, 2004;
279(49):
50639 - 50642.
[Full Text]
[PDF]
|
 |
|
|
|